Human primary liver cancer-derived organoid cultures for disease modeling and drug screening

Nature Medicine

Volumn 23, Issue 12, 2017, Pages 1424-1435

  Broutier, Laura ^a   Mastrogiovanni, Gianmarco ^a,b   Verstegen, Monique M A ^c   Francies, Hayley E ^d   Gavarró, Lena Morrill ^b   Bradshaw, Charles R ^a   Allen, George E ^a   Arnes Benito, Robert ^a   Sidorova, Olga ^a   Gaspersz, Marcia P ^c   Georgakopoulos, Nikitas ^b   Koo, Bon Kyoung ^b   Dietmann, Sabine ^b   Davies, Susan E ^e   Praseedom, Raaj K ^e   Lieshout, Ruby ^c   IJzermans, Jan N M ^c   Wigmore, Stephen J ^f   Saeb Parsy, Kourosh ^b   Garnett, Mathew J ^d   Van Der Laan, Luc J W ^c   Huch, Meritxell ^a,b   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG SCREENING; GENE EXPRESSION; GENOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; MALE; MOUSE; NONHUMAN; ORGANOID; PRIORITY JOURNAL; PROOF OF CONCEPT; TISSUE CULTURE; TUMOR XENOGRAFT; ANIMAL; BILE DUCT CARCINOMA; BILE DUCT TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; ISOLATION AND PURIFICATION; LIVER CELL CARCINOMA; LIVER TUMOR; NONOBESE DIABETIC MOUSE; PATHOLOGY; PERSONALIZED MEDICINE; PRIMARY CELL CULTURE; PROCEDURES; SCID MOUSE; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENT; TRANSCRIPTOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; ORGANOIDS; PRECISION MEDICINE; PRIMARY CELL CULTURE; TRANSCRIPTOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85039071691     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4438     Document Type: Article

References (73)

1. Bosch, F.X., Ribes, J., Díaz, M. & Cléries, R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127 (Suppl. 1), S5-S16 (2004).
2. Bridgewater, J. et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J. Hepatol. 60, 1268-1289 (2014).
3. Hirohashi, S. et al. Tumours of the Liver and Intrahepatic Bile Ducts. in World Health Organization Classification of Tumours (eds. Stanley R. Hamilton, M.D. & Lauri A. Aaltonen, M.D., Ph.D.) (IARCPress, 69372 Lyon, France, 2000).
4. Lee, S.D. et al. Clinicopathological features and prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgery. Hepatobiliary Pancreat. Dis. Int. 13, 594-601 (2014).
5. International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49, 658-664 (2009).
6. Marquardt, J.U. & Andersen, J.B. Liver cancer oncogenomics: opportunities and dilemmas for clinical applications. Hepat. Oncol. 2, 79-93 (2015).
7. Wang, A.-Q. et al. Combined hepatocellular cholangiocarcinoma: Controversies to be addressed. World J. Gastroenterol. 22, 4459-4465 (2016).
8. Sharma, S.V., Haber, D.A. & Settleman, J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat. Rev. Cancer 10, 241-253 (2010).
9. De Minicis, S. et al. Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma. Dig. Liver Dis. 45, 450-459 (2013).
10. Oikawa, T. et al. Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells. Nat. Commun. 6, 8070 (2015).
11. Shamir, E.R. & Ewald, A.J. Three-dimensional organotypic culture: experimental models of mammalian biology and disease. Nat. Rev. Mol. Cell Biol. 15, 647-664 (2014).
12. Ku, J.L. et al. Establishment and characterisation of six human biliary tract cancer cell lines. Br. J. Cancer 87, 187-193 (2002).
13. Cavalloni, G. et al. Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient. Tumour Biol. 37, 4041-4052 (2016).
14. Huch, M. & Koo, B.-K. Modeling mouse and human development using organoid cultures. Development 142, 3113-3125 (2015).
15. Hindley, C.J., Cordero-Espinoza, L. & Huch, M. Organoids from adult liver and pancreas: stem cell biology and biomedical utility. Dev. Biol. 420, 251-261 (2016).
16. Crespo, M. et al. Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing. Nat. Med. 23, 878-884 (2017).
17. Li, X. et al. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat. Med. 20, 769-777 (2014).
18. Sato, T. et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 141, 1762- 1772 (2011).
19. van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933-945 (2015).
20. Boj, S.F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324-338 (2015).
21. Gao, D. et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 159, 176-187 (2014).
22. Huch, M. et al. Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis. EMBO J. 32, 2708-2721 (2013).
23. Huch, M. et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wntdriven regeneration. Nature 494, 247-250 (2013).
24. Huch, M. et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell 160, 299-312 (2015).
25. Broutier, L. et al. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat. Protoc. 11, 1724-1743 (2016).
26. Brunt, E.M.P.V., Sempoux, C. & Theise, N.D. Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress. Hepat. Oncol. 2, 18 (2015).
27. Zhang, F. et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology 52, 224-232 (2008).
28. Zhao, Y.-J., Ju, Q. & Li, G.-C. Tumor markers for hepatocellular carcinoma. Mol. Clin. Oncol. 1, 593-598 (2013).
29. Ohguchi, S. et al. Expression of α-fetoprotein and albumin genes in human hepatocellular carcinomas: limitations in the application of the genes for targeting human hepatocellular carcinoma in gene therapy. Hepatology 27, 599-607 (1998).
30. Yakaboski, E., Jares, A. & Ma, Y. Stem cell gene SALL4 in aggressive hepatocellular carcinoma: a cancer stem cell-specific target? Hepatology 60, 419-421 (2014).
31. Yong, K.J. et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N. Engl. J. Med. 368, 2266-2276 (2013).
32. Moeini, A. et al. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. J. Hepatol. 66, 952-961 (2017).
33. Shibata, T. & Aburatani, H. Exploration of liver cancer genomes. Nat. Rev. Gastroenterol. Hepatol. 11, 340-349 (2014).
34. Woo, H.G. et al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res. 70, 3034-3041 (2010).
35. Kalinich, M. et al. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 114, 1123-1128 (2017).
36. Kamlua, S. et al. A novel TFF2 splice variant (EX2TFF2) correlates with longer overall survival time in cholangiocarcinoma. Oncol. Rep. 27, 1207-1212 (2012).
37. Banales, J.M. et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat. Rev. Gastroenterol. Hepatol. 13, 261-280 (2016).
38. Kraiklang, R. et al. A novel predictive equation for potential diagnosis of cholangiocarcinoma. PLoS One 9, e89337 (2014).
39. Andersen, J.B. et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 142, 1021-1031.e15 (2012).
40. Hsieh, S.Y. et al. Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol. Carcinog. 49, 476-487 (2010).
41. Blokzijl, F. et al. Tissue-specific mutation accumulation in human adult stem cells during life. Nature 538, 260-264 (2016).
42. Zou, S. et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat. Commun. 5, 5696 (2014).
43. Totoki, Y. et al. High-resolution characterization of a hepatocellular carcinoma genome. Nat. Genet. 43, 464-469 (2011).
44. Li, M.M. et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J. Mol. Diagn. 19, 4-23 (2017).
45. Schulze, K. et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet. 47, 505-511 (2015).
46. Borlak, J., Meier, T., Halter, R., Spanel, R. & Spanel-Borowski, K. Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene 24, 1809-1819 (2005).
47. Jiao, Y. et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat. Genet. 45, 1470- 1473 (2013).
48. Li, M. et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat. Genet. 43, 828-829 (2011).
49. Lee, Y.T. & Geer, D.A. Primary liver cancer: pattern of metastasis. J. Surg. Oncol. 36, 26-31 (1987).
50. Francies, H.E., Barthorpe, A., McLaren-Douglas, A., Barendt, W.J. & Garnett, M.J. Drug sensitivity assays of human cancer organoid cultures. In: Methods in Molecular Biology (Humana Press, 2016).
51. Morris, E.J. et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 3, 742-750 (2013).
52. Iorio, F. et al. A Landscape of Pharmacogenomic Interactions in Cancer. Cell 166, 740-754 (2016).
53. Drexler, H.G. et al. p53 alterations in human leukemia-lymphoma cell lines: in vitroartifact or prerequisite for cell immortalization? Leukemia 14, 198-206 (2000).
54. Frisch, S.M., Schaller, M. & Cieply, B. Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis. J. Cell Sci. 126, 21-29 (2013).
55. Gu, Q. et al. Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development. Oncotarget 6, 20160-20176 (2015).
56. Hidalgo, M. et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4, 998-1013 (2014).
57. Trapnell, C., Pachter, L. & Salzberg, S.L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111 (2009).
58. Liao, Y., Smyth, G.K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923-930 (2014).
59. Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
60. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
61. The UniProt Consortium. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 45, D158-D169 (2017).
62. Fang, H. & Gough, J. The 'dnet' approach promotes emerging research on cancer patient survival. Genome Med. 6, 64 (2014).
63. Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357-359 (2012).
64. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
65. Koboldt, D.C. et al. VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics 25, 2283-2285 (2009).
66. Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6, 80-92 (2012).
67. Sherry, S.T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308-311 (2001).
68. Lek, M. et al. Analysis of protein-coding genetic variation in 60, 706 humans. Nature 536, 285-291 (2016).
69. Forbes, S.A. et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43, D805-D811 (2015).
70. Sim, N.L. et al. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res. 40, W452-W457 (2012).
71. Galili, T. dendextend: an R package for visualizing, adjusting and comparing trees of hierarchical clustering. Bioinformatics 31, 3718-3720 (2015).
72. Colaprico, A. et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 44, e71 (2016).
73. Vis, D.J. et al. Multilevel models improve precision and speed of IC50 estimates. Pharmacogenomics 17, 691-700 (2016).